TScan Therapeutics, Inc. (NASDAQ:TCRX – Get Rating) was the target of a large increase in short interest in May. As of May 15th, there was short interest totalling 417,400 shares, an increase of 365.8% from the April 30th total of 89,600 shares. Approximately 2.9% of the company’s stock are sold short. Based on an average daily volume of 1,280,000 shares, the days-to-cover ratio is presently 0.3 days.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of TScan Therapeutics in a research note on Thursday, March 9th.
TScan Therapeutics Trading Up 31.3 %
TScan Therapeutics stock traded up $0.76 during midday trading on Friday, hitting $3.19. 3,685,387 shares of the stock were exchanged, compared to its average volume of 963,053. TScan Therapeutics has a fifty-two week low of $1.45 and a fifty-two week high of $6.03. The stock has a market capitalization of $77.28 million, a price-to-earnings ratio of -0.85 and a beta of 0.31. The stock’s 50-day simple moving average is $2.61 and its 200 day simple moving average is $2.37. The company has a current ratio of 7.18, a quick ratio of 7.18 and a debt-to-equity ratio of 0.38.
Institutional Investors Weigh In On TScan Therapeutics
Several institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC purchased a new stake in shares of TScan Therapeutics in the 2nd quarter worth about $32,000. Prudential Financial Inc. purchased a new stake in shares of TScan Therapeutics in the 3rd quarter worth about $34,000. Renaissance Technologies LLC purchased a new stake in shares of TScan Therapeutics in the 1st quarter worth about $37,000. LPL Financial LLC purchased a new stake in shares of TScan Therapeutics in the 2nd quarter worth about $50,000. Finally, Millennium Management LLC purchased a new stake in shares of TScan Therapeutics in the 4th quarter worth about $31,000. 48.21% of the stock is currently owned by hedge funds and other institutional investors.
TScan Therapeutics Company Profile
TScan Therapeutics, Inc, a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors.
- Get a free copy of the StockNews.com research report on TScan Therapeutics (TCRX)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.